Page last updated: 2024-12-06

tertatolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tertatolol: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36920
CHEMBL ID434200
CHEBI ID135244
SCHEMBL ID49634
MeSH IDM0047291

Synonyms (40)

Synonym
1-(tert-butylamino)-3-thiochroman-8-yloxypropan-2-ol
gtpl571
tertatolol (inn)
D07182
34784-64-0
83688-84-0
einecs 280-519-9
s-2395 ,
tertatolol
1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-2-propanol
dl-tertatolol
2-propanol, 1-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-
1-(tert-butylamino)-3-((3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy)propan-2-ol
racemic teraterol
CHEBI:135244
CHEMBL434200 ,
1-(tert-butylamino)-3-(3,4-dihydro-2h-thiochromen-8-yloxy)propan-2-ol
L001170
rac tertatolol
tertatolol(-)
1-tert-butylamino-3-(thiochroman-8-yloxy)-propan-2-ol(tertatolol)
bdbm50280934
1-tert-butylamino-3-(thiochroman-8-yloxy)-propan-2-ol
tertatolol [inn:ban]
unii-9zo341yqxp
9zo341yqxp ,
FT-0675301
tertatolol [who-dd]
tertatolol [inn]
tertatolol [mi]
(+/-)-1-(tert-butylamino)-3-(thiochroman-8-yloxy)-2-propanol
SCHEMBL49634
tert-butyl[3-(3,4-dihydro-2h-1-benzothiopyran-8-yloxy)-2-hydroxypropyl]amine
1-(tert-butylamino)-3-[(3,4-dihydro-2h-1-benzothiopyran-8-yl)oxy]propan-2-ol
CS-7407
HY-U00356
DB13775
Q7705238
DTXSID80865735
AKOS040742709

Research Excerpts

Overview

Tertatolol is a beta-blocker with unique renal vasodilatatory effects, mainly at the level of the microcirculation. It might be particularly useful in CsA-treated transplant recipients.

ExcerptReferenceRelevance
"Tertatolol is a noncardioselective beta-blocker without intrinsic sympathomimetic activity. "( The effects of tertatolol on lipid profile.
Amendt, K; Diehm, C; Jacobsen, O, 1993
)
2.08
"Tertatolol is a beta-blocker with unique renal vasodilatatory effects, mainly at the level of the microcirculation. "( Tertatolol: a beta-blocker with unique effects on human glomerular cell function.
Raij, L; Shultz, P, 1993
)
3.17
"Tertatolol is a new beta-blocker with specific vasodilatory properties, and thus might be particularly useful in CsA-treated transplant recipients."( Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A.
Branten, AJ; Hilbrands, LB; Huysmans, FT; Koene, RA; van Hamersvelt, HW, 1998
)
1.28
"Tertatolol is a new beta-adrenergic blocking agent that possesses unique actions on kidney function. "( Tertatolol increases glomerular filtration and urinary sodium in anesthetized rats.
Plante, GE; Prévost, C; Prost, JF; Rochat, C; Sirois, P, 1989
)
3.16
"Tertatolol is a potent beta-blocker with no intrinsic sympathomimetic activity (ISA) or beta 1/beta 2 receptor subtype selectivity. "( Reduction of beta-adrenergic receptors can explain the lack of rebound effect after tertatolol withdrawal.
De Blasi, A; Fratelli, M; Garattini, S; Pittana, PL, 1989
)
1.94
"Tertatolol is a potent new beta-blocker with no intrinsic sympathomimetic activity or beta 1/beta 2-receptor subtype selectivity. "( Reduction of beta-adrenergic receptors by tertatolol: an additional mechanism for beta-adrenergic blockade.
De Blasi, A; Garattini, S; Lipartiti, M; Pirone, F; Prost, JF; Rochat, C, 1986
)
1.98
"Tertatolol is a noncardioselective beta-adrenergic blocking agent without partial agonist activity. "( Tertatolol preserves renal perfusion in patients with arterial hypertension after head injury.
Brackman, F; Degaute, JP; Leeman, M; Naeije, R; Prost, JF; Thomas, J, 1986
)
3.16
"Tertatolol is a new potent beta-blocker without intrinsic sympathomimetic activity and lacking beta 1/beta 2 receptor subtype selectivity. "( Beta-adrenergic receptor changes during tertatolol treatment in healthy volunteers: relevance for beta-blocking therapy.
De Blasi, A; Garattini, S; Lipartiti, M, 1986
)
1.98
"Tertatolol is a new beta-blocking agent which induces renal vasodilation in experimental animals and humans and increases glomerular filtration rate (GFR), diuresis and natriuresis. "( Tertatolol ameliorates renal function in rats with chronic renal failure.
Delaini, F; Garattini, S; Lupini, C; Patino, O; Perico, N; Remuzzi, G; Tagliaferri, M, 1988
)
3.16

Effects

ExcerptReferenceRelevance
"Tertatolol has been studied in 2,338 patients with mild to moderate hypertension over a one year period. "( Tertatolol in hypertension. Long-term therapy in 2,338 patients.
Guery, O; Herpin, D; Lecasble, M; Piron, J, 1989
)
3.16

Actions

Tertatolol showed much lower affinity for 5-HT1B (Ki = 118.4 nM), 5- HT1C (K i = 699.6 nM) and5-HT2 (KI = 678.6nM) receptors. It does not cause the renal and mesenteric vaso-constriction observed following propranolol.

ExcerptReferenceRelevance
"(-)-Tertatolol showed much lower affinity for 5-HT1B (Ki = 118.4 nM), 5-HT1C (Ki = 699.6 nM) and 5-HT2 (Ki = 678.6 nM) receptors."( Tertatolol, a new beta-blocker, is a serotonin (5-hydroxytryptamine1A) receptor antagonist in rat brain.
Cagnotto, A; De Blasi, A; Esposito, E; Mennini, T; Prisco, S; Talone, D, 1993
)
2.21
"Tertatolol does not cause the renal and mesenteric vaso-constriction observed following propranolol."( Regional hemodynamic effects of the beta-adrenoceptor blockers tertatolol and propranolol in conscious spontaneously hypertensive rats.
Nievelstein, HM; Smits, JF; Struyker-Boudier, HA; Tijssen, CM, 1986
)
1.23

Treatment

Tertatolol (1 mg/kg, i.v.) potentiated the inhibitory effect of fluvoxamine on the basal activity of VTA dopaminergic neurons. Both tert atolol and enalapril treatments were associated with a similar decrease in mean arterial pressure.

ExcerptReferenceRelevance
"Both tertatolol and enalapril treatments were associated with a similar decrease in mean arterial pressure (-26 +/- 6 and -15 +/- 2 mm Hg, respectively, both p < 0.05 in comparison with baseline values) and left ventricular mass (echocardiography: -48 +/- 17 vs."( Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension.
Brouard, R; Du Cailar, G; Mimran, A; Ribstein, J, 1993
)
1.01
"(--)-Tertatolol treatment had no effect on the basal binding."( beta-Adrenoceptor regulation in rat heart, lung and skin after chronic treatment with (--)-tertatolol or (--)-propranolol.
Summers, RJ; Tan, YY, 1995
)
0.97
"Pretreatment with tertatolol (1 mg/kg, i.v.) potentiated the inhibitory effect of fluvoxamine on the basal activity of VTA dopaminergic neurons."( Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area.
Di Giovanni, G; Di Mascio, M; Di Matteo, V; Esposito, E; Prisco, S, 1998
)
0.62
"On treatment with tertatolol alone, maximum plasma concentrations were 123.7 +/- 32.4 ng/ml (mean +/- SD) and were reached after 1.95 +/- 1.77 hours."( Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.
Efthymiopoulos, C; Halabi, A; Jung, L; Kirch, W; Milferstädt, S; Rocher, I, 1990
)
0.96

Toxicity

ExcerptReferenceRelevance
" Biochemical surveillance did not show any adverse metabolic effects of tertatolol."( Overview of clinical safety and efficacy of tertatolol.
Vivet, P, 1993
)
0.78

Pharmacokinetics

Tertatolol was rapidly absorbed with a Cmax of 70 +/- 51 micrograms/l at a peak time of 0.5 mg/l. The tertatolOL elimination half-life was 9.5 hours.

ExcerptReferenceRelevance
"7 h) and peak concentration was 160 +/- 80 ng/mL."( Tertatolol in chronic renal failure. A pharmacokinetic study.
Meyrier, A; Mignon, F; Rainfray, M; Rocher, I, 1989
)
1.72
"An algorithm and computer program is presented that fits a largely non-parametric model to pharmacokinetic (PK) and pharmacodynamic (PD) data; it is an extension of a recently proposed approach."( Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.
Sheiner, LB; Verotta, D, 1987
)
0.27
"In this paper we propose a non-linear model for explaining the relation between doses, blood levels and pharmacodynamic effects."( Mathematical modelling accounting for discrepancies between blood levels and pharmacodynamic effects of a drug. Application to the numerical optimization of tertatolol.
Cherruault, Y; Hotchen, M; Karpouzas, I; Prost, JF, 1986
)
0.47

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here we determined whether the beta-adrenoceptor/5-HT1A receptor ligands (+/-)-pindolol, (-)-tertatolol and (-)-penbutolol, interact with paroxetine in a similar manner."( Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.
Clifford, EM; Cowen, PJ; Gartside, SE; Sharp, T, 1999
)
0.88

Bioavailability

ExcerptReferenceRelevance
"25 h) and totally absorbed by the gastro-intestinal tract with a low presystemic metabolism, and the bioavailability (60%) is not affected by food intake."( Biodisposition of tertatolol in man: a review.
Campbell, DB; Chignon, JC; Devissaguet, JP, 1986
)
0.6
" In comparison with healthy volunteers referred to in literature sources, plasma clearance was reduced to 49 +/- 28 ml/min, bioavailability was increased to 72 +/- 20%, and the volume of distribution was increased to 50 +/- 34 l, probably due, in part, to a weaker protein binding -85%--effect."( Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension.
Brouard, R; Caillau, H; Calès, P; Crambes, O; Desmorat, H; Jung, L; Pascal, JP; Rocher, I; Urien, S; Vinel, JP, 1993
)
0.55
" After oral administration of the pseudoracemate or of each enantiomer separately, no substantial difference in bioavailability were observed between the enantiomers."( Pharmacokinetics of the enantiomers of tertatolol in the rat after oral and intravenous administration.
Crambes, O; Efthymiopoulos, C; Gairard, A; Jung, L; Koffel, JC; Lave, T; Van Overloop, B, 1994
)
0.56

Dosage Studied

Tertatolol (T) was initiated alone (5 mg once daily) and if satisfactory control of blood pressure (BP) (diastolic BP less than 95 mm Hg) was not achieved, treatment was adapted. In trachea and right atria of the guinea-pig, tertAtolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol. The relative potency of tertatolOL was higher than that of propranolol.

ExcerptRelevanceReference
" We conclude that at effective beta-blocking dosage SE2395 does not induce any detrimental effect on renal function in conscious dogs."( Cardiovascular and renal effects of the beta-blocker SE2395 in conscious normotensive dogs.
Burke, TJ; Erickson, AL; Prost, JF; Rochat, C; Walker, BR,
)
0.13
" Tertatolol (T) was initiated alone (5 mg once daily) and if satisfactory control of blood pressure (BP) (diastolic BP less than 95 mm Hg) was not achieved, treatment was adapted at the third or sixth month either by increasing the dosage (heart rate greater than 70 beats/min), or by adding a potassium-sparing diuretic (heart rate less than or equal to 70 beats/min)."( Tertatolol in hypertension. Long-term therapy in 2,338 patients.
Guery, O; Herpin, D; Lecasble, M; Piron, J, 1989
)
2.63
" In trachea and right atria of the guinea-pig, tertatolol inhibited, in a concentration-dependent manner, the dose-response curves to isoproterenol; the relative potency of tertatolol was higher than that of propranolol."( Effects of tertatolol on post- and prejunctional beta adrenoceptors.
Herman, AG; Jordaens, FH; Laekeman, G; Majchrowicz, BB; Verbeuren, TJ; Zonnekeyn, LL, 1985
)
0.92
"We compared the central and renal haemodynamic effects of tertatolol, a new non-cardioselective beta-adrenergic blocking drug without partial agonist activity, with those of an equipotent dosage of propranolol in two groups of 10 patients each with acute cerebral injury who had developed systemic hypertension."( Acute central and renal haemodynamic responses to tertatolol and propranolol in patients with arterial hypertension following head injury.
Brackman, F; Degaute, JP; Leeman, M; Naeije, R; Prost, JF, 1986
)
0.77
" Its central and renal hemodynamic effects were compared to those of an equipotent dosage of propranolol in two groups of 10 patients each who developed arterial hypertension and a hyperdynamic circulatory state after head injury."( Tertatolol preserves renal perfusion in patients with arterial hypertension after head injury.
Brackman, F; Degaute, JP; Leeman, M; Naeije, R; Prost, JF; Thomas, J, 1986
)
1.71
" The kinetics are linear over a 10-fold dosage range and, after repeated dosing, there is no accumulation."( Biodisposition of tertatolol in man: a review.
Campbell, DB; Chignon, JC; Devissaguet, JP, 1986
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiochromaneAny organic heterobicyclic compound consisting of a benzene ring fused to a thiopyran.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.01860.00010.739610.0000AID4411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1346297Human beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1347018Rat beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID1346312Mouse beta3-adrenoceptor (Adrenoceptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors.
AID41892Tested for intrinsic sympathomimetic activity (ISA); pure antagonist1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID41488Selectivity for beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID40539Selectivity for beta-1 receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (52.31)18.7374
1990's53 (40.77)18.2507
2000's7 (5.38)29.6817
2010's1 (0.77)24.3611
2020's1 (0.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.13 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (21.17%)5.53%
Reviews7 (5.11%)6.00%
Case Studies1 (0.73%)4.05%
Observational0 (0.00%)0.25%
Other100 (72.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]